Parmax Pharma Ltd Financials
Company Logo

Parmax Pharma Ltd Financial Statement

Parmax Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue1.95
Operating Expense2.19
Net Profit-0.76
Net Profit Margin-38.97
Earning Per Share-2.04
EBIDTA-0.24
Effective Tax RateTBA

Parmax Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual28.20
Operating Expenses Annual27.95
Operating Profit Annual-0.78
Interest Annual0.59
Depreciation1.03
Net Profit Annual-2.09
Tax Annual-0.30

Parmax Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.05
Cash Flow from Operations-0.96
Cash Flow from Investing-0.70
Cash Flow from Financing1.40
Cash Flow at the End-0.21

Parmax Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)1.06
PBIT Margin (%)-2.59
PBT Margin (%)1.81
Net PROFIT Margin (%)-7.41
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-35.65
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)4.81

Parmax Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual7.97
Total Current Assets Annual10.00
Non Current Assets Annual8.75
Total Shareholders Funds Annual-1.99
Total Assets Annual18.75

Parmax Pharma Ltd Earning Calls

No Data Availabe

FAQS on Parmax Pharma Ltd Financials

As of Oct 3, 2025, Parmax Pharma Ltd has a market capitalization of 15.80 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Parmax Pharma Ltd is with a debt-to-equity ratio of -3.87.

In FY 2024 , Parmax Pharma Ltd recorded a total revenue of approximately 28.20 Cr marking a significant milestone in the company's financial performance.

Parmax Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.3% annually, respectively..

Parmax Pharma Ltd's current PE ratio is -7.56.

Parmax Pharma Ltd's ROCE averaged -30.9% from the FY ending March 2023 to 2025, with a median of -12.9%. It peaked at 4.0% in March 2023, reflecting strong capital efficiency over the period..

Parmax Pharma Ltd's latest EBIT is Rs. -1.81 Cr, surpassing the average EBIT of Rs. -2.14 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions